Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
SCYX
#3582
SCYNEXIS, Inc.
0.7
5
+4.17%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+4.17%
Monthly Change
-6.25%
6 month change
-9.64%
Year Change
-25.00%
Previous Close
0.7
2
Open
0.7
5
Bid
Ask
Low
0.7
5
High
0.7
5
Volume
3
Markets
US Stock Market
Healthcare
SCYX
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
37.95 M
38.98 M
39.02 M
41.92 M
41.97 M
—
Valuation ratios
Enterprise value
27.81 M
31.12 M
30.21 M
17.27 M
17.52 M
96.11 M
Price to earnings ratio
-2.22
-2.75
-1.7
-1.69
-1.51
-7.65
Price to sales ratio
8.43
15.67
17.6
10.17
12.95
56.4
Price to cash flow ratio
11.39
2.44
1.69
1.38
1.13
6.64
Price to book ratio
0.27
1.07
0.21
0.16
0.2
1.63
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.03
0.04
0.08
0.11
0.17
0.4
Return on equity %
0.05
0.07
0.11
0.15
0.24
0.56
Return on invested capital %
117.8
124.08
132.56
316.45
504.05
1 077.13
Gross margin %
100
100
100
100
100
400
Operating margin %
1 563.64
824.16
3 350.19
700.95
2 516.47
7 391.77
EBITDA margin %
—
—
—
—
—
—
Net margin %
425.45
369.6
2 097.67
504.77
2 572.16
5 544.19
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
3.13
3
5.83
5.2
5.75
19.78
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.01
0.01
0
0.02
0.01
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
0
0
0
—
Long term debt to total equity ratio
—
—
0
0
0
—
Per share metrics
Operating cash flow per share
-0.02
0.2
0.15
0.15
0.17
0.68
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
1.75
1.55
1.09
0.93
0.76
4.33
Net current asset value per share
1.65
1.49
1.06
1.14
0.98
4.66
Tangible book value per share
1.2
1.14
1.02
0.89
0.73
3.78
Working capital per share
1.13
0.99
0.88
0.92
0.81
3.59
Book value per share
1.2
1.14
1.02
0.89
0.73
3.78
News
SCYNEXIS doses first patients in SCY-247 IV formulation trial
JERSEY CITY - FDA grants fast track and QIDP designations to SCYNEXIS drug
Scynexis receives 180-day extension from Nasdaq to meet listing requirements
SCYNEXIS receives $7 million annual grant for antifungal research
Guggenheim lowers SCYNEXIS stock price target to $3 after GSK trial resolution
SCYNEXIS receives $22 million from GSK as MARIO study ends
Scynexis to receive $24.3 million from GSK as MARIO study ends per new agreement
SCYNEXIS reports positive Phase 1 results for antifungal drug SCY-247
Scynexis Inc earnings beat by $0.06, revenue topped estimates
SCYNEXIS resumes Phase 3 antifungal study after FDA lift
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update